Skip to main content
. Author manuscript; available in PMC: 2016 Jun 8.
Published in final edited form as: Cancer Cell. 2015 Jun 8;27(6):864–876. doi: 10.1016/j.ccell.2015.05.004

Figure 5. A2-32-01 inhibits ClpP and is cytotoxic to AML cells.

Figure 5

(A) Effect of A2-32-01 on the ability of recombinant human ClpP and ClpX to cleave the fluorogenic substrate casein-FITC. Mean ± SD.

(B) Effect of A2-32-01 on ClpP activity measured in mitochondrial lysates from OCI-AML2 and TEX cells after 2 hr based on cleavage of the fluorogenic substrate Suc-LY-AMC. Percent mean ± SD.

(C) Effect of 48 hr A2-32-01 treatment on the activity of ClpP in HL60, K562, OCI-AML2, and TEX cells based on the cleavage of the fluorogenic substrate Suc-LY-AMC. Normalized data are shown.

(D) Effect of 48 hr A2-32-01 treatment on the viability of HL60, K562, OCI-AML2, and TEX cells. Percent mean ± SD of viable cells was measured by trypan blue staining.

(E) Effect of 48 hr A2-32-01 treatment on the viability of WT and Rho (0) 143B cells. Percent of viable cells was measured by trypan blue staining.

See also Figure S4.